ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q sales grew sequentially in both academic and community settings Focused pipeline progressing with continued LOTIS-7 dose escalation, screening patients for ADCT-601 targeting AXL in pancreatic cancer, and advancing differentiated solid tumor research platform FY 2023 operating expenses decreased 21%1 year-over-year due to portfolio prioritization and operational efficiencie

Related Keywords

New Jersey , United States , London , City Of , United Kingdom , Switzerland , China , Deerfield , American , Lausanne Biop , Nicole Riley , Drug Administration , Mitsubishi Tanabe Pharma Corporation , American Society Of Hematology , Company On , Md Anderson Cancer Center , European Commission , American Association For Cancer Research , Exchange Commission , European Union , University Of Miami , Company Annual Report On Form , Data Monitoring Committee , Company On Linkedin , Development Rd Expenses , European Medicines Agency , Ameet Mallik , Chief Executive Officer , Independent Data Monitoring Committee , Initiated Trial , American Society , Cancer Center , American Association , Cancer Research , Annual Meeting , Adjusted Net , San Francisco Bay Area , Accepted Accounting Principles , Based Compensation Expense , Facility Agreement , Healthcare Royalty , Private Securities Litigation Reform Act , Swedish Orphan Biovitrum , European Economic Area , Healthcare Royalty Management , Blue Owl , Annual Report , Balance Sheet , Months Ended December , Ended December ,